Due to a system-wide technology update, we are experiencing extremely high call volume. We appreciate your patience with our operators during this time. Thank you for choosing Fox Chase Cancer Center.
Multicenter Pancreatic Cyst Trial Headed by Fox Chase Researcher Launches
PHILADELPHIA (January 16, 2020)—An eight-year multicenter trial to study how often and how fast pancreatic cysts progress to cancer is launching today. Fox Chase Cancer Center serves as the headquarters for the project, although the trial is open to participation at hundreds of sites around the country.
The main focus of the new trial is to compare the clinical effectiveness of two surveillance strategies used to track pancreatic cysts. Researchers will also look at the costs of cyst surveillance, the impact on patients of long-term follow-up, and attempt to identify novel molecular markers and radiology findings that may predict the behavior of these cysts, said David S. Weinberg, MD, MSc, chair of the Department of Medicine at Fox Chase and principal investigator for the trial.
Pancreatic cysts occur in at least 20 percent of the older population. They are an important and identifiable precursor to pancreatic cancer, the fourth leading cause of cancer death in the United States. Cysts are typically not symptomatic when discovered, usually when someone is getting a CAT scan or an MRI for something else.
“Most cysts won’t turn into cancer. However, because of the risk, many patients may consider surgery. It’s a big operation and we want to make sure that only those patients at the greatest cancer risk get surgery,” Weinberg said.
There are two main guidelines for management of pancreatic cysts. The first is the Fukuoka guidelines, which were formulated in 2006 and revised several times since then. In 2015, the American Gastroenterological Association (AGA) published different, more streamlined guidelines.
Weinberg said the AGA guidelines recommend fewer and less frequent diagnostic tests, which means less money is spent, but it is not clear if clinical outcomes differ between the two sets of guidelines. That question was the genesis of the research, which will be a prospective trial that seeks to enroll 5,000 patients randomized to one of the two protocols. This is not the first comparative trial, but it is the first of its size and length. The trial is being funded by the National Cancer Institute.
“Nobody’s under any illusion that either surveillance strategy as currently written is good enough. They are the best we have for now, but we are looking for something better,” Weinberg said.
Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.
For more information, call 888-369-2427